Related Experiment Videos
Serotherapy of ovarian cancer
Abstract:
The development of monoclonal antibodies has permitted the identification of several ovarian-tumor-associated antigens which might serve as targets for serotherapy in vivo. With the exception of antibodies directed against growth factor receptors, unmodified monoclonal reagents must activate complement (C') components or bind effector cells to destroy tumor targets. Antibody-dependent cell-mediated cytotoxicity (ADCC) may be particularly important for eliminating tumor cells in vivo. A shortage of functionally active effector cells can limit the efficacy of serotherapy with heteroantisera or monoclonal reagents. The use of immunostimulants such as Corynebacterium parvum has increased the number and activity of effector cells for ADCC within the peritoneal compartment of mice and of patients with ovarian cancer. Intraperitoneal serotherapy can achieve direct contact between antibody and microscopic deposits of ovarian tumor cells which persist following cytoreductive operations and cytotoxic chemotherapy. Conjugation of monoclonal antibodies with radionuclides, drugs or toxins might increase the potency of serotherapy and circumvent the effector shortage. Clinical studies to date have evaluated radionuclide conjugates for imaging and for therapy. Patients with a small volume of disease have responded to treatment. Preclinical models suggest that drug and toxin conjugates might also prove active. Recent studies have demonstrated a synergistic interaction between different immunotoxins. Ovarian carcinoma is likely to be a valuable clinical model for evaluating immunoconjugates which react with epithelial tumor cells.
Insights
Monoclonal antibodies target ovarian cancer antigens for serotherapy. Enhancing effector cells or using antibody conjugates may improve treatment efficacy against persistent tumor cells.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Monoclonal antibodies identify ovarian tumor antigens for serotherapy.
- Unmodified antibodies require complement (C') or effector cells for tumor cell destruction.
- Antibody-dependent cell-mediated cytotoxicity (ADCC) is crucial for in vivo tumor cell elimination.
Purpose of the Study:
- To explore strategies for enhancing serotherapy efficacy in ovarian cancer.
- To investigate the role of effector cells and antibody conjugates in ovarian tumor treatment.
Main Methods:
- Utilizing monoclonal antibodies against ovarian tumor-associated antigens.
- Employing immunostimulants like Corynebacterium parvum to boost effector cell activity.
- Evaluating antibody conjugates (radionuclide, drug, toxin) for enhanced potency.
Main Results:
- Immunostimulants increase effector cell numbers and ADCC activity in ovarian cancer models.
- Intraperitoneal serotherapy facilitates direct antibody-tumor cell contact.
- Clinical studies show patient response to radionuclide conjugates, especially with low disease volume.
Conclusions:
- Ovarian cancer serves as a key model for evaluating immunoconjugates targeting epithelial tumor cells.
- Strategies to overcome effector cell limitations and enhance antibody potency are critical for serotherapy success.